Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

351,441 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 10/22/2020.
Displaying: 668 trials in your specialties ()
View trials across your selected specialties

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Breast Cancer
View Full Trial
INTERVENTION

Drug: Ipatasertib, Drug: Paclitaxel, Drug: Atezolizumab, Drug: Nab-Paclitaxel, Drug: AC

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Pacific Shores Medical Group, Long Beach, California, United States

Brief Summary

This is a study consisting of four cohorts in this setting. In Cohort 1, the safety and efficacy of ipatasertib (ipat) in combination with atezolizumab (atezo) and paclitaxel (pac) or nab-paclitaxel will be evaluated for participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not previously received chemotherapy. In Cohort 2, ipatasertib and atezolizumab (with no chemotherapy), will be administered to participants with locally advanced or metastatic TNBC. In Cohort 3, the safety and efficacy of neoadjuvant ipatasertib, atezolizumab, doxorubicin and cyclophosphamide (AC) (Ipat + Atezo + AC) followed by Ipat + Atezo + Pac will be evaluated in participants with locally advanced Type 2-4 (T2-4) TNBC. In Cohort 4, the safety and efficacy of Ipat + Atezo + Pac will be evaluated in participants with PD-L1 (Programmed Death-Ligand-1) positive locally advanced or metastatic TNBC that is not amenable to resection and who have not previously received chemotherapy in the advanced setting.

A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Advanced Pancreatic Cancer
View Full Trial
INTERVENTION

Biological: Nivolumab, Drug: Fluorouracil, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Leucovorin, Drug: Irinotecan Hydrochloride, Biological: Cabiralizumab, Drug: Nab-paclitaxel, Drug: Onivyde

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Mayo Clinic - PPDS, Phoenix, Arizona, United States

Brief Summary

The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.

A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 1
  • Condition
    Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: FOLFIRINOX or gemcitabine/abraxane, Radiation: SBRT

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Colorado, Aurora, Colorado, United States

Brief Summary

This is a dose escalation trial to evaluate the safety of stereotactic body radiotherapy (SBRT) delivered in 3 fractions for patients with locally advanced pancreatic cancer (LAPC) who have received induction chemotherapy (FOLFIRINOX or gemcitabine and nab-paclitaxel).

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
View Full Trial
INTERVENTION

Drug: Gemcitabine combined with nab-paclitaxel, Drug: Dose -SM-88, Drug: Dose -mFOLFIRINOX

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States

Brief Summary

Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives - To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in 1st and/or 2nd line metastatic pancreatic cancer patients and determine which, if any, patients benefit from each investigational arm. Secondary Objectives - To determine short and long-term safety signals of each investigational arm in pancreatic cancer patients vs. SOC. - To determine progression-free survival (PFS) for each investigational arm vs. SOC. - Rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). - Rate of clinical benefit; duration of clinical benefit.

A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

  • Status
    Recruiting
  • Phase
    Phase 1
  • Condition
    Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal ...
View Full Trial
INTERVENTION

Drug: CDX-1140, Drug: CDX-301, Drug: Pembrolizumab, Drug: Chemotherapy

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

HonorHealth Research Insititute, Scottsdale, Arizona, United States

Brief Summary

This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Tri...
View Full Trial
INTERVENTION

Biological: CAN04, Drug: Cisplatin, Drug: Gemcitabine, Drug: Nab-paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Landeskrankenhaus Salzburg, Salzburg, Austria

Brief Summary

This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors. Following completion of the first part, the dose escalation cohorts, and determination of maximum tolerated dose or recommended phase 2 dose (MTD/RP2D), safety and tolerability will be further evaluated in an expanded cohort of subjects with pancreatic or lung cancer, as monotherapy or in combination with the standard of care treatment. In addition, early signs of efficacy during treatment with CAN04 will be investigated.

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Small Cell Lung Cancer (SCLC)
View Full Trial
INTERVENTION

Drug: Nab-paclitaxel, Drug: Gemcitabine

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Brief Summary

The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Gastroesophageal Cancer
View Full Trial
INTERVENTION

Drug: nab-paclitaxel, Biological: ramucirumab

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Rocky Mountain Cancer Centers, Denver, Colorado, United States

Brief Summary

The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab (Cyramza®) are effective when used in combination for treating patients with metastatic gastroesophageal cancer who have either progressed or not responded to prior therapy.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer...
View Full Trial
INTERVENTION

Drug: Adavosertib, Drug: Gemcitabine Hydrochloride, Other: Laboratory Biomarker Analysis, Drug: Nab-paclitaxel, Other: Pharmacological Study, Other: Placebo Administration

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Northwestern University, Chicago, Illinois, United States

Brief Summary

This partially randomized phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 when given together with paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride and how well they work in treating patients with previously untreated pancreatic cancer that has spread to another place in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride are more effective with or without WEE1 inhibitor MK-1775 in treating patients with pancreatic cancer.

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

  • Status
    Recruiting
  • Phase
    Phase 3
  • Condition
    Advanced or Metastatic Breast Cancer
View Full Trial
INTERVENTION

Drug: Trastuzumab deruxtecan, Drug: Capecitabine, Drug: Paclitaxel, Drug: Nab-Paclitaxel

Eligibility
  • Ages:
  • Sexes: All
  • Accepts Healthy Volunteers:
Locations

Research Site, Madrid, Spain

Brief Summary

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.